1208069-55-9

Basic information

• Product Name: 6-chloro-3-iodo-2-methylimidazo[1,2-b]pyridazine
• Synonyms: 6-chloro-3-iodo-2-methylimidazo[1,2-b]pyridazine
• CAS NO: 1208069-55-9
• Molecular Formula: C₇H₅ClIN₃
• Molecular Weight: 293.49217
• Mol File: 1208069-55-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloro-3-iodo-2-methylimidazo[1,2-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-3-iodo-2-methylimidazo[1,2-b]pyridazine(1208069-55-9)
• EPA Substance Registry System: 6-chloro-3-iodo-2-methylimidazo[1,2-b]pyridazine(1208069-55-9)

Safety Data

• Hazardous Substances Data: 1208069-55-9(Hazardous Substances Data)

Usage

General Description

6-chloro-3-iodo-2-methylimidazo[1,2-b]pyridazine is a chemical compound with the molecular formula C7H5ClIN3. It is a heterocyclic compound that consists of a fused pyridazine and imidazole ring system, with chlorine and iodine atoms attached to the pyridazine ring, and a methyl group attached to the imidazole ring. 6-chloro-3-iodo-2-methylimidazo[1,2-b]pyridazine is used in organic synthesis and medicinal chemistry research, and its properties and reactivity make it potentially useful in the development of pharmaceuticals and agrochemicals. It is important to handle this compound with caution, as it may pose health and environmental hazards if not managed properly.

Upstream product

• 14793-00-1 6-chloro-2-methylimidazo-<1,2-b>pyridazine 

Downstream Products

• 1228217-21-7 2-Methyl-6-[(R)-3-methylpiperazin-1-yl]-3-{1-[(4-methylphenyl)sulphonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl}imidazo[1,2-b]pyridazine 
• 1208069-57-1 6-Chloro-2-methyl-3-(2-methoxypyridin-4-yl)imidazo[1,2-b]pyridazine 
• 1208069-60-6 {4-[6-(5-benzylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-methylimidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl}amine 
• 1208069-63-9 {4-[6-(5-benzylhexahydropyrrolo[3,4-c]pyrrol-2-yl)-2-methylimidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl}methylamine 

Relevant articles and documents

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF

The invention relates to 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives of the general formula (I) where: R2 is a C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkyloxy-C-M-alkyl, C3-7-cycloalkyloxy-C1-4-alkyl>C3-7-cycloalkyl-C1-4-alkyloxy-C1-4-alkyl, hydroxy-C1-6-alkyl, C1-4-fluoroalkyl group; R3 is a hydrogen atom or a substituent selected from halogen atoms and the C1-3 alkyl, —NR4R5, hydroxyl or C1-4 alkyloxy groups; A is a C1-7-alkylene group optionally substituted by one or two Ra groups; B is a C1-7-alkylene group optionally substituted by one or two Rb groups; L is either a nitrogen atom optionally substituted by an Rc or Rd group or a carbon atom substituted by an Re1 group and an Rd group or by two Re2 groups; Rd is a group selected from a hydrogen atom or a C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-alkylthio-C1-6-alkyl, C1-6-alkyloxy-C1-6-alkyl, C1-6-fluoroalkyl, hydroxy-C1-6-alkyl group; Rf is a C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-alkyloxy-C1-6-alkyl, C3-7-cycloalkyloxy-C1-4-alkyl, C3-7-cycloalkyl-C1-4-alkyloxy-C1-4-alkyl, hydroxy-C1-6-allyl, C1-6-fluoroalkyl or benzyl group. The invention also relates to a method for preparing same and to the therapeutic application thereof.